Log in

View Full Version : General Cancer News

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 [45] 46 47 48 49 50 51 52 53 54 55 56
  1. Stimuvax clinical program resumed in patients with NSCLC (0 replies)
  2. Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC (0 replies)
  3. Brazilian breast cancer drug market to grow from $424M in 2009 to $611M in 2014: Deci (0 replies)
  4. Report reveals increase in patients influence on success, failure of new drugs (1 replies)
  5. AVEO granted patents for tests to identify cancer patients likely to respond to tivoz (0 replies)
  6. Exercise helps patients recover shoulder movement after breast cancer surgery (0 replies)
  7. Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-li (0 replies)
  8. Cancer overtreatment raises concern; Physicians tend to use new technology even befor (0 replies)
  9. ARBs may be linked with increased risk of developing cancer: US scientists (0 replies)
  10. CombiMatrix Diagnostics receives final licensure documentation and approvals to begin (0 replies)
  11. Women who drink boiled coffee at lower risk of breast cancer (1 replies)
  12. NBC's TODAY Show to focus on PF in an interview with a patient from California (0 replies)
  13. Xoft reports clinical benefits of isotope-free electronic radiation therapy for treat (0 replies)
  14. Medicare coverage of unproven mammography screening device leads to surge in usage (0 replies)
  15. 2,300 researchers under one roof at American Society of Echocardiography 21st Annual (0 replies)
  16. ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variant (0 replies)
  17. Radiation scans cause increased scrutiny (0 replies)
  18. UCB announces availability of Vimpat oral solution formulation (0 replies)
  19. Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC (0 replies)
  20. Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at AS (0 replies)
  21. Nurse with enhanced clinical skills detects same breast abnormalities as surgeon (0 replies)
  22. ARBs increase risk of cancer: Study (0 replies)
  23. New guideline to improve IHC testing for expression status of ER and PgR in breast ca (0 replies)
  24. How Carly Fiorina can cure her hot-mic 'hair' gaffe (cancer survivor) (0 replies)
  25. DRIVE4COPD initiative aims to raise awareness of COPD (0 replies)
  26. Study results of genes regulated by ERB published in Journal of Biological Chemistry (0 replies)
  27. Eribulin mesylate drug may help extend lives of women with advanced breast cancer (0 replies)
  28. AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting (0 replies)
  29. HL survivors do not receive recommended cancer screening tests: Study (0 replies)
  30. Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma (0 replies)
  31. Budget cuts, poor fiscal management threaten breast cancer screening for needy women (0 replies)
  32. Interpretation of multiple gene function may hold clue to autism (0 replies)
  33. CTT's Calmare Pain Therapy Treatment shows promise against CIPN (0 replies)
  34. SBUMC uses RapidArc radiotherapy technology to treat cancer patients (0 replies)
  35. UAB researchers win grant to study metastasis of dead cancer cells (0 replies)
  36. Older breast cancer women in Scotland do not receive same level of treatment as young (0 replies)
  37. Ashikari Breast Center to participate in TARGiT intra-operative radiotherapy trial (0 replies)
  38. iCAD to supply CAD technology for mammography to VA, Department of Defense Hospitals (0 replies)
  39. Are Dead Cancer Cells Feeding Cancer's Spread? (0 replies)
  40. EC approves Nivestim for prevention of FN (0 replies)
  41. 22 Midwest facilities named Centers of Excellence in accelerated partial breast irrad (0 replies)
  42. Baylor Institute of Immunology Research receives nearly $35M as grants in 2009 (1 replies)
  43. Scientists discover how polyphenols present in red wine and green tea inhibit prostat (0 replies)
  44. NICE decides not to recommend lapatinib for women with advanced breast cancer (0 replies)
  45. Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metasta (0 replies)
  46. University of Missouri researchers to investigate cadmium's potential for causing end (0 replies)
  47. Stress-reducing psychological intervention helps increase quality of life among women (0 replies)
  48. Multiple presentations on nab-driven chemotherapy at 46th ASCO (0 replies)
  49. Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline (0 replies)
  50. Breast tomosynthesis holds promise for early breast cancer detection (0 replies)
  51. Psychological intervention program teaches breast cancer patients how to cope with th (0 replies)
  52. Breast cancer research showcased at ASCO Annual Meeting (0 replies)
  53. New technique to prevent tumours developing in connection with stem cell transplantat (0 replies)
  54. Clarient granted U.K. patent for TLE3 biomarker (0 replies)
  55. Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-res (0 replies)
  56. Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC pres (0 replies)
  57. Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer (0 replies)
  58. Genta presents tesetaxel dose-ranging trial results at ASCO 2010 (0 replies)
  59. GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia (0 replies)
  60. Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% (0 replies)
  61. Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at AS (0 replies)
  62. ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma a (0 replies)
  63. Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at (0 replies)
  64. Lawsuit to be launched over breast cancer gene patent (0 replies)
  65. Teen researches Artemesinin for cancer (0 replies)
  66. Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Me (0 replies)
  67. Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at AS (0 replies)
  68. Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2 (0 replies)
  69. BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation (0 replies)
  70. Chronix's serum DNA assays have potential to detect early stage breast cancer, prosta (0 replies)
  71. Clinical trial data of imetelstat in patients with breast cancer presented at ASCO an (0 replies)
  72. Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Hea (0 replies)
  73. AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recu (0 replies)
  74. Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metasta (0 replies)
  75. Bisphosphonates may cause poorer survival rate in women with early stage breast cance (3 replies)
  76. bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index cl (0 replies)
  77. Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive m (0 replies)
  78. Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced bre (0 replies)
  79. Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented a (0 replies)
  80. Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be pr (0 replies)
  81. New clinical research findings on oncology to be highlighted at ASCO 2010 (0 replies)
  82. USC to present promising new findings in cancer research at 2010 ASCO (0 replies)
  83. Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway target (0 replies)
  84. Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 20 (0 replies)
  85. Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASC (0 replies)
  86. Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC (0 replies)
  87. Antiemetic-regimen with fosaprepitant injection provides similar protection against C (0 replies)
  88. Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemo (0 replies)
  89. Life Technologies partners to create Genomic Cancer Care Alliance (0 replies)
  90. Chemotherapy-induced amenorrhea improves survival in premenopausal women with early s (0 replies)
  91. China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million (0 replies)
  92. Wolverine Venture Fund participates in $8M series A round of financing for Delphinus (0 replies)
  93. ELLICSR research centre opened at UHN (0 replies)
  94. BSGI effective for evaluating unclear mammographic or ultrasound findings (0 replies)
  95. Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study (0 replies)
  96. Discovery reveals a new approach to target cancer (0 replies)
  97. Study provides personalized strategies to boost AIAA compliance in breast cancer pati (0 replies)
  98. Researchers identify new therapeutic target for cognitive decline (0 replies)
  99. Nanosponge delivery system more effective at reducing tumor growth than direct inject (0 replies)
  100. Extracts from peach and plum kill breast cancer cells, say AgriLife Research scientis (0 replies)
  101. PMRT increases breast cancer patients' five-year overall survival by almost 50%: Stud (0 replies)
  102. Olive oil produces greater weight loss in breast cancer survivors: Researchers (0 replies)
  103. Discovery provides new therapeutic target to prevent loss of brain function (0 replies)
  104. Chronix Biomedical to launch new disease detection, monitoring service for cancer res (0 replies)
  105. Genes influence AIAA side effect in breast cancer survivors (0 replies)
  106. Targeted monoclonal antibodies show promise for pancreatic and metastatic breast canc (0 replies)
  107. Oncimmune develops new blood test to aid early detection of cancer (0 replies)
  108. TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine (0 replies)
  109. FDA grants priority review status to Eisai's eribulin NDA (0 replies)
  110. Prototype breast cancer vaccine shows promising results on mice (0 replies)
  111. Cancer patients should find ways to be physically active during and after treatment: (0 replies)
  112. GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis (0 replies)
  113. Elekta acquires Resonant Medical (0 replies)
  114. Free educational forum tailored to the needs of people diagnosed with breast cancer (0 replies)
  115. IMRT avoids xerostomia, but effectiveness on controlling cancer unclear (0 replies)
  116. Women who undergo bilateral oophorectomy tend to have smaller tumors (0 replies)
  117. Crowne Plaza Invitational at Colonial hosts second annual Pink Out to raise awareness (0 replies)
  118. Exposure in womb to BPA, DES increase offspring's risk of breast cancer (0 replies)
  119. LCRF to donate $25,000 for lung cancer studies at TGen (0 replies)
  120. Health law implementation deadlines missed, GOP offers repeal bill (0 replies)
  121. Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: (0 replies)
  122. Thyroid cancer gene marker (0 replies)
  123. First Edition: May 28, 2010 (0 replies)
  124. IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report (0 replies)
  125. Amgen announces European approval of Prolia (0 replies)
  126. Active charity supporter nominated for Breast Cancer Campaign's Fundraiser of the Yea (0 replies)
  127. Local school nominated for Breast Cancer Campaign's School of the Year award (0 replies)
  128. Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, a (0 replies)
  129. Local businesswoman nominated for Outstanding Contribution to Breast Cancer Campaign (0 replies)
  130. Study finds improvement in detection of breast cancer in mammograms over 9-year perio (0 replies)
  131. Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: St (0 replies)
  132. Study assesses possible links between pain medications and recurrent breast cancer ri (0 replies)
  133. Breast-conserving therapy is viable treatment option for African-American women: Rese (0 replies)
  134. Highlights from June 2010 issue of American Journal of Pathology (0 replies)
  135. Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept (0 replies)
  136. RCSI researchers identify biomarker that can predict severity of breast cancer (0 replies)
  137. State Roundup: Oklahoma, S.C. and Ill. facing tough choices on health costs (0 replies)
  138. Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells (0 replies)
  139. ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO (0 replies)
  140. Regulators puzzling out what insurers must do under new health law (0 replies)
  141. Delphinus Medical Technologies secures $8M in venture capital to commercialize SoftVu (0 replies)
  142. Scientists develop DNA-vaccine that restricts supply of blood to tumours (0 replies)
  143. Abviva receives new patent grant notifications for MSA technology (0 replies)
  144. Women exposed prenatally to BPA or DES at increased risk of breast cancer: Study (0 replies)
  145. New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010 (0 replies)
  146. Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2 (0 replies)
  147. Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presen (0 replies)
  148. New data highlighting Pfizer's approach to cancer drug development to be presented at (0 replies)
  149. Researchers discover key gene that promotes development of common kidney cancer (0 replies)
  150. Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian can (0 replies)
  151. Provectus to present further positive data from PV-10 Phase 2 clinical trial for meta (0 replies)
  152. ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma (0 replies)
  153. 'Teachable moments' can reduce cancer risk in children of parents with mutations in t (0 replies)
  154. Data from three Phase II clinical trials of PS-targeting antibody to be presented at (0 replies)
  155. Genentech to present new data for targeted cancer medicines at 46th ASCO (0 replies)
  156. Loved ones can fill in gaping blanks about brain cancer patients' well-being: Study (0 replies)
  157. Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin (1 replies)
  158. Nine facilities in northern California region named Centers of Excellence in accelera (0 replies)
  159. Canadian Cancer Statistics 2010 focuses on care, support for dying patients (0 replies)
  160. British Columbians lead the way in battle against cancer (0 replies)
  161. 70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommenda (0 replies)
  162. Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study (0 replies)
  163. Research shows improved treatment of severe epilepsy reduces overall cost of the cond (0 replies)
  164. Wellpoint CEO Braly faces sharp criticism at shareholders meeting (0 replies)
  165. ASCO first peek (0 replies)
  166. University of Arkansas to host the 2010 Advances in Breast Cancer Research workshop (0 replies)
  167. Generex Biotechnology's Phase I study data of AE37 for prostate cancer published (0 replies)
  168. Researchers discover biological pathway signature of ccRCC (0 replies)
  169. Neoprobe gamma radiation detection systems featured in RSL peer review in American Jo (0 replies)
  170. Abviva receives Japanese patent for Mammastatin Serum Assay (0 replies)
  171. Woman with higher blood levels of IGF-I more likely to develop breast cancer: Study (0 replies)
  172. 152 research and training grants awarded to researchers at 93 institutions nationwide (0 replies)
  173. Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal (0 replies)
  174. Cancer 'epidemic' isn't happening (0 replies)
  175. United Spinal Association and ICS co-sponsor first annual conference to empower women (0 replies)
  176. Twenty rising juniors to create bras during summer break (0 replies)
  177. Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award (0 replies)
  178. EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers (0 replies)
  179. Power3 Medical Products files provisional patent applications with USPTO (0 replies)
  180. Novartis employees and colleagues join together to raise money for community organiza (0 replies)
  181. BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million (0 replies)
  182. Measuring gene expression in healthy women may predict future breast cancer risk, say (0 replies)
  183. New research to improve treatment for oesophageal and upper stomach cancer (0 replies)
  184. DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary (0 replies)
  185. Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010 (0 replies)
  186. TechniScan awarded U.S. Patent covering design of 3-D, Warm Bath Ultrasound system (0 replies)
  187. CyGene Laboratories reports heightened interest in at-home genetic testing (0 replies)
  188. 27-year-old sickle cell disease patient undergoes multiple joint replacement surgery (0 replies)
  189. Researchers develop new approach to immunotherapy of cancer (0 replies)
  190. CTI to conduct phase II study of pixantrone in metastatic breast cancer through NCCTG (0 replies)
  191. Older women want more information about breast cancer, breast screening: Survey (0 replies)
  192. Genetic tests represent future of cancer care for women (0 replies)
  193. New computer-based tool developed to benefit cancer patients (0 replies)
  194. Tensions escalate between Obama administration, health insurers (0 replies)
  195. Exelixis first-quarter revenues increase to $42.2 million (0 replies)
  196. Bionovo reports net loss of $4.7M for first-quarter 2010 (0 replies)
  197. Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in p (0 replies)
  198. Minn. negotiators seek compromise to expand Medicaid while a nursing home tax and cut (0 replies)
  199. Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24% (0 replies)
  200. New combination therapy may help treat anti-estrogen resistant ER+ breast cancer (0 replies)
  201. Enzon reports income from continuing operations of $20.8M for first-quarter 2010 (0 replies)
  202. More genetic sites associated with increase in breast cancer risk discovered (0 replies)
  203. Double mastectomy best for long-term prognosis of breast cancer (0 replies)
  204. Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin (0 replies)
  205. Discovery of new genetic clues to breast cancer (0 replies)
  206. Creator of California Tay-Sachs Disease Prevention Program among the honorees (0 replies)
  207. NPWH launches ETIQ campaign to improve access to information about menopause, estroge (0 replies)
  208. New research examines coping and appraisal of disease-related pain (0 replies)
  209. Gene patenting policies affect patient access to testing for disease-causing genes: S (0 replies)
  210. Progestins increase chances of cancer metastasizing, finds study (0 replies)
  211. Natazia tablets receive FDA approval for prevention of pregnancy (0 replies)
  212. A checklist to stay healthy at every age (0 replies)
  213. Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million (0 replies)
  214. Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH re (0 replies)
  215. Research reveals role of ovarian hormone progesterone in alteration of breast stem ce (0 replies)
  216. CU-Boulder develops inhalable vaccine for measles prevention (0 replies)
  217. Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter (0 replies)
  218. Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010 (0 replies)
  219. Whole body MRI helps physicians diagnose and treat breast cancer: Study (0 replies)
  220. Watson Laboratories files raloxifene hydrochloride tablet ANDA (0 replies)
  221. Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010 (0 replies)
  222. C. R. Bard reaches definitive agreement to acquire SenoRx (0 replies)
  223. Survey reveals need for educating U.S. women about stroke symptoms (0 replies)
  224. Principals of StemTroniX, Power3 Medical Products file patent application (0 replies)
  225. FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis pat (0 replies)
  226. Scientists discover key molecular mechanism in breast cancer metastasis (0 replies)
  227. Popular diabetes drug works differently than thought (0 replies)
  228. Celldex reports net loss of $6.6 million for first-quarter 2010 (0 replies)
  229. Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study (0 replies)
  230. GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11 (0 replies)
  231. Celsion reports $4.6 million net loss from operations for first-quarter 2010 (0 replies)
  232. Study comparing enteroscopy technologies finds SE quicker than DBE for examining smal (0 replies)
  233. Drive for expediency should not compromise care in breast cancer diagnosis, treatment (0 replies)
  234. Broccoli component sulforaphane targets and kills breast cancer stem cells (0 replies)
  235. NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in His (0 replies)
  236. NIH awards UIC $10M grant to study health disparities among underserved, minority wom (0 replies)
  237. FDA issues advisory on prostate cancer drugs (0 replies)
  238. Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma (0 replies)
  239. BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development (0 replies)
  240. PEAK Surgical announces positive results from two PRECISE Clinical Studies for breast (0 replies)
  241. BSGI improves breast cancer detection (0 replies)
  242. New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor (0 replies)
  243. Research roundup: Managing nursing home patients, streamlining medical billing, finan (0 replies)
  244. ZIOPHARM reports a net loss of $17.7 million in first quarter 2010 (0 replies)
  245. Obese women more likely to have breast cancer at later stage: Study (0 replies)
  246. Smoking can increase risk of second cancer in breast cancer survivors (0 replies)
  247. McGill scientist discovers how one particular gene regulates epithelial cells (0 replies)
  248. Leading experts deliver breast cancer updates at unique public forum (0 replies)
  249. Update on BioSante cancer vaccine portfolio to be presented at BIO International Conv (0 replies)
  250. HHS Secretary to host web chat to discuss impact of newly passed health insurance ref (0 replies)